{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sanchez J"],"funding":["Horizon 2020 Framework Programme","NIAID NIH HHS","Seventh Framework Programme"],"pagination":["586124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7683801"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11"],"pubmed_abstract":["<h4>Background</h4>Our previous work has demonstrated the benefits of transcutaneous immunization in targeting Langerhans cells and preferentially inducing CD8 T-cell responses.<h4>Methods</h4>In this randomized phase Ib clinical trial including 20 HIV uninfected volunteers, we compared the safety and immunogenicity of the MVA recombinant vaccine expressing HIV-B antigen (MVA-B) by transcutaneous and intramuscular routes. We hypothesized that the quality of innate and adaptive immunity differs according to the route of immunization and explored the quality of the vector vaccine-induced immune responses. We also investigated the early blood transcriptome and serum cytokine levels to identify innate events correlated with the strength and quality of adaptive immunity.<h4>Results</h4>We demon"],"journal":["Frontiers in immunology"],"pubmed_title":["Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study."],"pmcid":["PMC7683801"],"funding_grant_id":["P01 AI131568"],"pubmed_authors":["Bonduelle O","Esteban M","Gomez CE","Perez S","Combadiere B","Soria A","Vogt A","Sanchez J","Llano A","Mothe B","Lama JR","Fernandez-Maldonado M","Garcia F","Goncalves E","Gonzales P","Fernandez MA","de Bernard S","Pedruzzi E","Brander C","Cedeno S","Nourikyan J","Ganoza C"],"additional_accession":[]},"is_claimable":false,"name":"Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study.","description":"<h4>Background</h4>Our previous work has demonstrated the benefits of transcutaneous immunization in targeting Langerhans cells and preferentially inducing CD8 T-cell responses.<h4>Methods</h4>In this randomized phase Ib clinical trial including 20 HIV uninfected volunteers, we compared the safety and immunogenicity of the MVA recombinant vaccine expressing HIV-B antigen (MVA-B) by transcutaneous and intramuscular routes. We hypothesized that the quality of innate and adaptive immunity differs according to the route of immunization and explored the quality of the vector vaccine-induced immune responses. We also investigated the early blood transcriptome and serum cytokine levels to identify innate events correlated with the strength and quality of adaptive immunity.<h4>Results</h4>We demon","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2026-04-08T02:59:46.276Z","creation":"2021-02-20T00:56:29Z"},"accession":"S-EPMC7683801","cross_references":{"pubmed":["33244316"],"doi":["10.3389/fimmu.2020.586124"]}}